scispace - formally typeset
L

Lisa S. Rotenstein

Researcher at Brigham and Women's Hospital

Publications -  62
Citations -  3189

Lisa S. Rotenstein is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Medicine & Health care. The author has an hindex of 11, co-authored 40 publications receiving 1900 citations. Previous affiliations of Lisa S. Rotenstein include University of California, San Francisco & California State University, Northridge.

Papers
More filters
Journal ArticleDOI

Prevalence of Depression, Depressive Symptoms, and Suicidal Ideation Among Medical Students: A Systematic Review and Meta-Analysis.

TL;DR: A systematic review of studies on the prevalence of depression, depressive symptoms, or suicidal ideation in medical students published before September 17, 2016 found that strategies for preventing and treating these disorders in this population of medical students are needed.
Journal ArticleDOI

Prevalence of Burnout Among Physicians: A Systematic Review

TL;DR: There was substantial variability in prevalence estimates of burnout among practicing physicians and marked variation in burnout definitions, assessment methods, and study quality.
Journal ArticleDOI

Making Patients and Doctors Happier — The Potential of Patient-Reported Outcomes

TL;DR: Interviews with providers suggest that incorporating collection of patient-reported outcomes into routine care can improve physician satisfaction, enhance physician–patient relationships, increase workflow efficiency, and enable crucial conversations.
Journal ArticleDOI

Identification of Racial Inequities in Access to Specialized Inpatient Heart Failure Care at an Academic Medical Center.

Lauren A. Eberly, +228 more
TL;DR: Black and Latinx patients were less likely to be admitted to cardiology for HF care, and admission to the cardiology service was independently associated with decreased readmission within 30 days, independent of race.
Journal ArticleDOI

Opportunities and Challenges for Biosimilars: What's on the Horizon in the Global Insulin Market?

TL;DR: Biosimilar insulins have the potential to reduce diabetes treatment costs, increase the accessibility of insulin treatment, and expand the number of insulin brands available for those with diabetes, but they will have to overcome numerous regulatory hurdles, meet a variety of commercial demands, and effectively confront competition from both established and next-generation branded insulin products before they can succeed on the global market.